scholarly journals Use of the brain parenchymal fraction to measure whole brain atrophy in relapsing-remitting MS

Neurology ◽  
2011 ◽  
Vol 76 (22) ◽  
pp. 1893-1893
Author(s):  
R. A. Rudick ◽  
E. Fisher ◽  
J.- C. Lee ◽  
J. Simon ◽  
L. Jacobs ◽  
...  
Keyword(s):  
Brain Atrophy ◽  
Whole Brain ◽  
Relapsing Remitting ◽  
Brain Parenchymal Fraction ◽  
Brain Parenchymal ◽  
The Brain

scholarly journals Use of the brain parenchymal fraction to measure whole brain atrophy in relapsing-remitting MS

Neurology ◽  
1999 ◽  
Vol 53 (8) ◽  
pp. 1698-1698 ◽  
Author(s):  
R. A. Rudick ◽  
E. Fisher ◽  
J.-C. Lee ◽  
J. Simon ◽  
L. Jacobs
Keyword(s):  
Brain Atrophy ◽  
Whole Brain ◽  
Relapsing Remitting ◽  
Brain Parenchymal Fraction ◽  
Brain Parenchymal ◽  
The Brain

Robustness of the brain parenchymal fraction for measuring brain atrophy

2002 ◽  
Author(s):  
M. Stella Atkins ◽  
Jeffery J. Orchard ◽  
Benjamin Law ◽  
Melanie K. Tory
Keyword(s):  
Brain Atrophy ◽  
Brain Parenchymal Fraction ◽  
Brain Parenchymal ◽  
The Brain

Relationship between brain atrophy and disability: an 8-year follow-up study of multiple sclerosis patients

2000 ◽  
Vol 6 (6) ◽  
pp. 373-377 ◽  
Author(s):  
E Fisher ◽  
R A Rudick ◽  
G Cutter ◽  
M Baier ◽  
D Miller ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Disease Progression ◽  
Brain Atrophy ◽  
Phase Iii ◽  
Phase Iii Trial ◽  
Follow Up Study ◽  
Relapsing Remitting ◽  
Brain Parenchymal Fraction ◽  
Brain Parenchymal

Brain atrophy measurement can provide an estimate of the amount of tissue destruction due to the pathologic processes in multiple sclerosis. The potential usefulness of atrophy as a marker of disease progression depends upon the concurrent and predictive relationships between atrophy and disability. A follow-up study was performed to measure atrophy and disability scores in patients from the Multiple Sclerosis Collaborative Research Group's phase III trial of IFNb-1a (Avonex) in relapsing-remitting multiple sclerosis. New data were obtained on 160 out of 172 eligible patients from the original trial were enrolled in the follow-up study approximately 8 years after randomization. The follow-up visit consisted of several tests and questionnaires including a clinical exam to determine Expanded Disability Status Score (EDSS) and Multiple Sclerosis Functional Composite (MSFC), and a magnetic resonance imaging exam to calculate the brain parenchymal fraction. Brain parenchymal fraction was correlated with both EDSS and MSFC at each of the four time points for which data were available (baseline 1, 2 and 8 years). Furthermore, the change in BPF was correlated with the changes in disability scores from the end of the phase III trial to the follow-up exam. These data suggest that brain atrophy may be a useful and clinically relevant marker of disease progression in relapsing-remitting MS.

Has your patient's multiple sclerosis lesion burden or brain atrophy actually changed?

2004 ◽  
Vol 10 (4) ◽  
pp. 402-406 ◽  
Author(s):  
Xingchang Wei ◽  
Charles RG Guttmann ◽  
Simon K Warfield ◽  
Michael Eliasziw ◽  
J Ross Mitchell
Keyword(s):  
Multiple Sclerosis ◽  
Measurement Error ◽  
Brain Tissue ◽  
Brain Atrophy ◽  
Multiple Sclerosis Lesion ◽  
Lesion Volume ◽  
Measurement Variability ◽  
Brain Parenchymal Fraction ◽  
Significant Change ◽  
Brain Parenchymal

Changes in mean magnetic resonance imaging (MRI)-derived measurements between patient groups are often used to determine outcomes in therapeutic trials and other longitudinal studies of multiple sclerosis (MS). However, in day-to-day clinical practice the changes withinindividual patients may also be of interest. In this paper, we estimated the measurement error of an automated brain tissue quantification algorithm and determined the thresholds for statistically significant change of MRI-derived T2 lesion volume and brain atrophy in individual patients. Twenty patients with MS were scanned twice within 30 min. Brain tissue volumes were measured using the computer algorithm. Brain atrophy was estimated by calculation of brain parenchymal fraction. The threshold of change between repeated scans that represented statistically significant change beyond measurement error with 95% certainty was 0.65 mL for T2 lesion burden and 0.0056 for brain parenchymal fraction. Changes in lesion burden and brain atrophy below these thresholds can be safely (with 95% certainty) explained by measurement variability alone. These values provide clinical neurologists with a useful reference to interpret MRI-derived measures in individual patients.

scholarly journals Toward MRI-based whole-brain health assessment: The brain atrophy and lesion index (BALI)

2018 ◽  
Vol 1 (1) ◽  
pp. 55-63 ◽  
Author(s):  
Lukas A. Grajauskas ◽  
Hui Guo ◽  
Ryan C.N. D'Arcy ◽  
Xiaowei Song
Keyword(s):  
Brain Atrophy ◽  
Health Assessment ◽  
Brain Health ◽  
Whole Brain ◽  
The Brain ◽  
Lesion Index

Frontal parenchymal atrophy measures in multiple sclerosis

2004 ◽  
Vol 10 (5) ◽  
pp. 562-568 ◽  
Author(s):  
Laura Locatelli ◽  
Robert Zivadinov ◽  
Attilio Grop ◽  
Marino Zorzon
Keyword(s):  
Multiple Sclerosis ◽  
Cognitive Functions ◽  
Brain Atrophy ◽  
Neuropsychological Functioning ◽  
Intraclass Correlation ◽  
Quantitative Mri ◽  
Cross Sectional ◽  
Regional Brain ◽  
Brain Parenchymal Fraction ◽  
Brain Parenchymal

The aim of this study was to establish whether, in a cross-sectional study, the normalized measures of whole and regional brain atrophy correlate better with tests assessing the cognitive function than the absolute brain atrophy measures. The neuropsychological performances and disability have been assessed in 39 patients with relapsing-remitting multiple sclerosis (MS). T1- and T2-lesion load (LL) of total brain and frontal lobes (FLs) were measured using a reproducible semiautomated technique. The whole brain volume and the regional brain parenchymal volume (RBPV) of FLs were obtained using a computerized interactive program, which incorporates semiautomated and automated segmentation processes. Normalized measures of brain atrophy, i.e., brain parenchymal fraction (BPF) and regional brain parenchymal fraction (RBPF) of FLs, were calculated. The scan-rescan, inter- and intrarater coefficient of variation (COV) and intraclass correlation coefficient (ICC) have been estimated. The RBPF of FLs showed an acceptable level of reproducibility which ranged from 1.7% for intrarater variability to 3.2% for scan-rescan variability. The mean ICC was 0.88 (CI 0.82-0.93). The RBPF of FLs demonstrated stronger magnitudes of correlation with neuropsychological functioning, disability and quantitative MRI lesion measures than RBPV. These differences were statistically significant: P=0.001 for Stroop Color Word Interference test, P=0.001 for Paced Auditory Serial Addition Test, P=0.04 for Standard Raven Progressive Matrices, P=0.049 for Expanded Disability Status Scale, P=0.01 for T2-LL of FLs and P< 0.001 for T1-LL of FLs. BPF demonstrated significant correlations with tests assessing cognitive functions, whereas BPAV did not. The correlation analysis results were supported by the results of multiple regression analysis which showed that only the normalized brain atrophy measures were associated with tests exploring the cognitive functions. These data suggest that RBPF is a reproducible and sensitive method for measuring frontal parenchymal atrophy. The normalized measures of whole and regional brain parenchymal atrophy should be preferred to absolute measures in future studies that correlate neuropsychological performances and brain atrophy measures in patients with MS.

Anti-GM1 antibodies are not associated with cerebral atrophy in patients with multiple sclerosis

2009 ◽  
Vol 15 (1) ◽  
pp. 114-115 ◽  
Author(s):  
P Valentino ◽  
A Labate ◽  
R Nisticò ◽  
D Pirritano ◽  
A Cerasa ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Brain Atrophy ◽  
Plasma Sample ◽  
Cerebral Atrophy ◽  
Serum Levels ◽  
Automated Method ◽  
Relapsing Remitting ◽  
Mri Study ◽  
Relapsing Remitting Multiple Sclerosis ◽  
The Brain

Objectives The aim of this study was to correlate the brain atrophy with serum levels of anti-GM1 antibodies in patients with relapsing–remitting multiple sclerosis (RRMS). Methods Plasma sample from 52 patients with RRMS and 65 healthy controls were examined for anti-GM1 antibodies. Patients with RRMS underwent to MRI study with automated method called SIENAX that calculated an estimate of gray matter (GMV) and white matter (WMV) volumes. Results The percentage of RRMS patients with increased anti-GM1 was 37.8%. Elevated levels of anti-GM1 antibodies did not correlate with brain atrophy. Conclusions Anti-GM1 antibodies do not represent a marker of axonal damage in patients with RRMS.

Brain atrophy in relapsing multiple sclerosis: relationship to relapses, EDSS, and treatment with interferon β-1a

2000 ◽  
Vol 6 (6) ◽  
pp. 365-372 ◽  
Author(s):  
Richard A Rudick ◽  
Elizabeth Fisher ◽  
Jar-Chi Lee ◽  
Jeffrey T Duda ◽  
Jack Simon
Keyword(s):  
Multiple Sclerosis ◽  
Clinical Trial ◽  
Brain Atrophy ◽  
Surrogate Marker ◽  
Phase Iii ◽  
Therapeutic Effects ◽  
Lesion Volume ◽  
Interferon Β ◽  
Brain Parenchymal ◽  
The Brain

Brain atrophy is a relevant surrogate marker of the disease process in multiple sclerosis (MS) because it represents the net effect of various pathological processes leading to brain tissue loss. There are various approaches to quantifying central nervous system atrophy in MS. We have focused on a normalized measure of whole brain atrophy, the brain parenchymal fraction (BPF). BPF is defined as the brain parenchymal volume, divided by the volume within the surface of the brain. We applied this method to an MRI data set generated during a phase III clinical trial of interferon β-1a (AVONEX). The purpose of the current study is to further explore clinical and MRI correlates of the BPF, particularly as they relate to relapse rate and Kurtzke's Expanded Disability Status Score (EDSS); and to further explore the therapeutic effects observed in interferon β-1a recipients. Of all demographic and disease measures in the clinical trial data base, T2 lesion volume most closely correlated with BPF in cross sectional studies, and was the baseline factor most closely correlated with progressive brain atrophy in the subsequent 2 years. We also observed that change in T2 lesion volume was the disease measure most closely correlated with change in BPF during 2 years of observation. Of interest, relapse number and EDSS change during 2 years were only weakly correlated with BPF change during the same period. Disability progression, defined as sustained worsening of at least 1.0 EDSS points from baseline, persisting at least 6 months, was associated with significantly greater brain atrophy progression. We observed a therapeutic effect of interferon β-1a in the second year of the clinical trial, and this beneficial effect was not accounted for by change in gadolinium enhanced lesion volume, or by corticosteroid medication within 40 days of the final MRI scan. The BPF is an informative surrogate marker for destructive pathological processes in relaping MS patients, and is useful in demonstrating treatment effects in controlled clinical trials. The significance of progressive brain atrophy during relapsing MS will be assessed by measuring clinical and MRI changes in prospective follow up studies.

Sign in / Sign up

Export Citation Format

Share Document